PDUFA dates May 2024: FDA calendar and catalysts.
2 PDUFA dates fell in May 2024: CARDAMYST (May 2024), ABEO (May 25). The FDA calendar also recorded 18 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.
PDUFA dates in May 2024
| PDUFA date | Company | Ticker | Drug | Indication | Source |
|---|---|---|---|---|---|
| May 2024 | Milestone Pharmaceuticals Inc. | MIST | CARDAMYST (etripamil) | SEC 8-K Exhibit 99.1, filed 2025-03-13 | |
| May 25, 2024 | ABEONA THERAPEUTICS INC. | ABEO | Not named | SEC Form 10-Q, filed 2024-11-14 |
Download: CSV · JSON · iCal (next 30 days, CC BY 4.0) · Calendar API · All months
May 2024: other FDA decisions and filings
| Date | Drug | Company | Event | Indication | Status | Source |
|---|---|---|---|---|---|---|
| May 2024Month disclosed | CARDAMYST (etripamil) | MIST | NDA/BLA accepted | — | Completed | SEC 8-K Exhibit 99.1 |
| May 2024Month disclosed | AUSTEDO (deutetrabenazine) | TEVA | FDA approval | — | Approved | SEC 8-K Exhibit 99.1 |
| May 16, 2024 | Imdelltra (tarlatamab-dlle) | AMGN | FDA approval | To treat extensive stage small cell lung cancer | Approved | FDA Novel Drug Approvals |
| May 16, 2024 | Benlysta (belimumab) | GSK | Label expansion | — | Approved | openFDA Drugs@FDA |
| May 25, 2024 | — | ABEO | NDA/BLA accepted | — | Completed | SEC Form 10-K |
| May 28, 2024 | Bkemv (eculizumab-aeeb) | AMGN | FDA approval | — | Approved | openFDA Drugs@FDA |
| May 29, 2024 | Retevmo (selpercatinib) | LLY | Label expansion | — | Approved | openFDA Drugs@FDA |
| May 31, 2024 | Cefazolin In Dextrose (cefazolin sodium) | BAX | Label expansion | — | Approved | openFDA Drugs@FDA |
May 2024: dated readouts
| Date | Drug | Company | Event | Indication | Status | Source |
|---|---|---|---|---|---|---|
| May 2024Month disclosed | uproleselan | CBIO | Topline readout | — | Mixed | SEC Form 10-Q |
| May 2024Month disclosed | — | CTXR | Topline readout | — | Positive | sec_424b |
| May 2024Month disclosed | — | INSM | Topline readout | — | Positive | SEC Form 10-Q |
| May 2024Month disclosed | FG-3246 | KYNB | Interim readout | mCRPC | Positive | SEC Form 10-Q |
| May 2024Month disclosed | — | ORGO | Topline readout | — | Met primary endpoint | SEC Form 10-Q |
| May 2024Month disclosed | pariglasgene brecaparvovec (DTX401) | RARE | Topline readout | aged eight years and older | Positive | SEC Form 10-K |
| May 2024Month disclosed | — | SABS | Topline readout | — | Positive | sec_424b |
| May 3, 2024 | ABP-450 | AEON | Interim readout | — | Missed primary endpoint | SEC Form 10-Q |
May 2024: trial starts and primary completions
| Date | Drug | Company | Event | Indication | Status | Source |
|---|---|---|---|---|---|---|
| May 2024Month disclosed | sabirnetug (ACU193) | ABOS | Trial start | — | Completed | SEC Form 10-K |
| May 15, 2024 | andersen | NMAD | Trial start | ovarian clear cell carcinoma | Completed | SEC Form 10-Q |
2 more milestones are guided to a half-year or full-year window, or estimated from ClinicalTrials.gov primary completion dates, that overlaps May 2024. They are on each drug page and in the calendar API.
Questions
What PDUFA dates are in May 2024?
2 PDUFA dates fell in May 2024: CARDAMYST (May 2024), ABEO (May 25). The FDA calendar also recorded 18 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.
Can these dates change?
Yes. The FDA can extend a review by three months after a major amendment, and it sometimes acts before the goal date. Each row links the filing the date came from.
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.